We are live on ! Find out more
FA

Forefront Analytics Portfolio holdings

AUM $110M
1-Year Est. Return 18.54%
This Fund
S&P 500
This Quarter Est. Return
-7.86%
1 Year Est. Return
+18.54%
3 Year Est. Return
+33.55%
5 Year Est. Return
+24.76%
10 Year Est. Return
–
AUM
$188M
AUM Growth
-$18.7M
Cap. Flow
-$2M
Cap. Flow %
-1.07%
Top 10 Hldgs %
59.57%
Holding
70
New
4
Increased
27
Reduced
26
Closed
4

Top Buys

1
UNH icon
UnitedHealth
UNH
+$348K
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$198K
3
WIP icon
State Street SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
+$175K
4
VWO icon
Vanguard FTSE Emerging Markets ETF
VWO
+$157K
5
JSPR icon
Jasper Therapeutics
JSPR
+$156K

Top Sells

1
NULV icon
Nuveen ESG Large-Cap Value ETF
NULV
+$1.27M
2
VNQ icon
Vanguard Real Estate ETF
VNQ
+$704K
3
GILD icon
Gilead Sciences
GILD
+$251K
4
HSIC icon
Henry Schein
HSIC
+$223K
5
DBEF icon
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
+$223K

Sector Composition

1 Healthcare 1.2%
2 Industrials 0.22%
3 Financials 0.19%
4 Technology 0.16%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
51
Annexon
ANNX
$950M
$98K 0.05%
16,055
-4,830
-23% -$26.1K
MREO
52
Mereo BioPharma
MREO
$49.5M
$96K 0.05%
112,800
+36,950
+49% +$45.2K
JSPR icon
53
Jasper Therapeutics
JSPR
$24.8M
$94K 0.05%
11,980
+8,517
+246% +$156K
DYAI icon
54
Dyadic International
DYAI
$45.9M
$77K 0.04%
40,546
-6,225
-13% -$16.6K
THRX
55
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$74K 0.04%
+13,065
New +$92.3K
ACHL
56
DELISTED
Achilles Therapeutics
ACHL
$72K 0.04%
+32,200
New +$91.1K
CTMX icon
57
CytomX Therapeutics
CTMX
$788M
$71K 0.04%
47,869
+11,950
+33% +$18.4K
SURF
58
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$70K 0.04%
66,838
+25,150
+60% +$40.2K
PRVB
59
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$68K 0.04%
14,997
-6,430
-30% -$29.3K
KGC icon
60
Kinross Gold
KGC
$27B
$60K 0.03%
16,000
– –
PSTX
61
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$59K 0.03%
15,650
-7,720
-33% -$25.5K
DM
62
DELISTED
Desktop Metal, Inc.
DM
$55K 0.03%
2,131
– –
ORTX
63
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$54K 0.03%
10,004
+740
+8% +$4.12K
CDAK
64
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$47K 0.03%
56,485
+38,175
+208% +$80.1K
GERN icon
65
Geron
GERN
$924M
$44K 0.02%
17,586
-17,150
-49% -$38.4K
ADAM
66
Adamas Trust
ADAM
$807M
$23K 0.01%
2,500
– –
GILD icon
67
Gilead Sciences
GILD
$167B
– –
-4,051
Closed -$251K
HSIC icon
68
Henry Schein
HSIC
$10B
– –
-2,891
Closed -$223K
UBX
69
DELISTED
Unity Biotechnology
UBX
– –
-2,038
Closed -$11K
EIGR
70
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-384
Closed -$73K
1 2
3

Similar funds

NC
nVerses Capital Wellington, Florida $110M AUM
PXPO
Peak XV Partners Operations Trianon, Mauritius $110M AUM 43.09% 1-Year Est. Return
OWA
OakTrust Wealth Advisors Wilton, Connecticut $110M AUM
MCM
Masterton Capital Management New York $110M AUM 3.55% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
NA
NWM Advisors San Luis Obispo, California $110M AUM
NMC
New Mountain Capital New York $110M AUM 51.63% 1-Year Est. Return
BCM
Bond Capital Management San Francisco, California $110M AUM 16.91% 1-Year Est. Return

Forefront Analytics's Q3 2022 Portfolio in Review

As of Q3 2022, Forefront Analytics held 70 positions worth $188M, down 9% from $206M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Forefront Analytics's Q3 2022 filing shows 4 new, 27 increased, 26 reduced and 4 closed positions. Its largest new stake was UnitedHealth: 662 shares worth $339K. The largest sale was Nuveen ESG Large-Cap Value ETF, an estimated $1.27M.

By sector, the portfolio is most concentrated in Healthcare at 1.2% of assets, up from 1.1% a quarter earlier, followed by Industrials and Financials.

  • Forefront Analytics's largest Q3 2022 buy was UnitedHealth: 662 shares worth $339K.
  • Forefront Analytics added most to State Street SPDR FTSE International Government Inflation-Protected Bond ETF in Q3 2022, an estimated $175K increase.
  • Forefront Analytics's biggest Q3 2022 reduction was Nuveen ESG Large-Cap Value ETF, cutting an estimated $1.27M.
  • Forefront Analytics fully exited Gilead Sciences in Q3 2022, selling an estimated $251K.
  • Forefront Analytics's ten largest holdings make up 60% of its $188M portfolio in Q3 2022.
  • Forefront Analytics opened 4 new positions and closed 4 in Q3 2022.
  • Forefront Analytics's portfolio value fell 9% quarter-over-quarter to $188M.

Based on Forefront Analytics's 13F filing for Q3 2022, filed 14 Nov 2022.